NCT04762030招募中2 期
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
Shanghai Pulmonary Hospital, Shanghai, China1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2021年2月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- PFS at 24 months
研究概览
简要总结
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent provided.
- •Males or females aged ≥18 years.
- •Pathologically diagnosed of non-small cell lung cancer.
- •Diagnosed as stage III.
- •Tumor should be considered resectable before study entry by a multidisciplinary team.
- •ECOG (Performance status) 0-
- •Screening laboratory values must meet the following criteria and should be obtained within 7 days prior to treatment.
- •i. Neutrophils ≥ 1500×109/L ii. Platelets ≥ 100 x×109/L iii. Hemoglobin > 9.0 g/dL iv. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min v. AST/ALT ≤ 3 x ULN vi. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) vii. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters or >40% predicted value viii. INR/APTT within normal limits.
- •Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 7 days before randomization.
- •All sexually active men and women of childbearing potential must use an effective contraceptive method (two barrier methods or a barrier method plus a hormonal method) during the study treatment and for a period of at least 12 months following the last administration of trial drugs.
- •Patient capable of proper therapeutic compliance and accessible for correct follow-up.
- •Measurable or evaluable disease (according to RECIST 1.1 criteria).
排除标准
- •All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.
- •central type, with empty lung squamous cell carcinoma or non-small cell lung cancer with hemoptysis (>50 mL/day).
- •Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function. In case of doubt please contact trial team.
- •Patients with other active malignancy requiring concurrent intervention and/or concurrent treatment with other investigational drugs or anti-cancer therapy.
- •Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
- •Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.
- •Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
- •Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
- •Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •Patients with history of allergy to study drug components excipients. Women who are pregnant or in the period of breastfeeding.
- •Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
研究组 & 干预措施
Experimental Group
Experimental
干预措施: Durvalumab Anlotinib Carboplatin Nab-paclitaxel (Drug)
结局指标
主要结局
PFS at 24 months
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
The PFS is defined as the time from diagnosis to relapse, progression or death, whichever occurred first.
次要结局
未报告次要终点
研究者
Chang Chen
Vice-President of Shanghai Pulmonary Hospital
Shanghai Pulmonary Hospital, Shanghai, China
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung CancerResectable Stage IIA to IIIB Non-small Cell Lung CancerNCT05500092Montefiore Medical Center17
终止
2 期
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerNon Small Cell Lung CancerNCT04422392Shanghai Pulmonary Hospital, Shanghai, China93
招募中
3 期
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal CancerEsophageal CancerNCT05547529Blokhin's Russian Cancer Research Center156
终止
2 期
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder CancerBladder AdenocarcinomaBladder Mixed AdenocarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma With Giant CellsInfiltrating Bladder Urothelial Carcinoma With Glandular DifferentiationInfiltrating Bladder Urothelial Carcinoma With Trophoblastic DifferentiationInfiltrating Bladder Urothelial Carcinoma, Clear Cell VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Nested VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantNCT03912818Stanford University7
终止
2 期
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinMuscle-invasive Bladder CancerNCT03234153Insel Gruppe AG, University Hospital Bern6